Inspire Medical Systems (NYSE:INSP) Stock Rating Upgraded by Barclays

Inspire Medical Systems (NYSE:INSP) was upgraded by investment analysts at Barclays to a “strong sell” rating in a report released on Tuesday, Zacks reports.

INSP has been the subject of a number of other reports. Freedom Capital upgraded shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Truist Financial reaffirmed a “hold” rating and issued a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Royal Bank Of Canada raised their price objective on shares of Inspire Medical Systems from $60.00 to $75.00 and gave the stock a “sector perform” rating in a report on Thursday, October 1st. Finally, Robert W. Baird upped their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $67.29.

Inspire Medical Systems Stock Performance

INSP stock opened at $66.50 on Tuesday. The firm has a market cap of $1.92 billion, a P/E ratio of 14.39, a P/E/G ratio of 5.10 and a beta of 0.73. The firm’s fifty day moving average is $64.86 and its 200 day moving average is $54.06. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue was down 7.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Inspire Medical Systems

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its position in Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares during the period. Versant Capital Management Inc lifted its holdings in Inspire Medical Systems by 379.0% in the second quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock valued at $43,000 after acquiring an additional 758 shares during the period. GAMMA Investing LLC boosted its position in Inspire Medical Systems by 85.0% in the second quarter. GAMMA Investing LLC now owns 1,221 shares of the company’s stock worth $54,000 after purchasing an additional 561 shares during the last quarter. State of Wyoming grew its stake in shares of Inspire Medical Systems by 83.7% during the 1st quarter. State of Wyoming now owns 1,343 shares of the company’s stock valued at $69,000 after purchasing an additional 612 shares during the period. Finally, Nykredit A S purchased a new stake in shares of Inspire Medical Systems during the 2nd quarter valued at about $78,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.